Abstract
The definition of the myelodysplastic syndrome (MDS) subtype ‘MDS with isolated del(5q)’ was expanded to include cases with one additional non-chromosome 7 based cytogenetic abnormality in the 2016 revised World Health Organization classification. This study applied the revised definition to a large primary MDS cohort, and evaluated the prognostic impact of the additional cytogenetic abnormality. Seventy-two of 1067 patients (7%) met the ‘MDS with isolated del(5q)’ criteria, 11 (1%) of whom had an additional cytogenetic abnormality. There was no survival difference between patients in whom del(5q) occurred alone, compared to those with one additional cytogenetic abnormality (P = 0·52).
Original language | English (US) |
---|---|
Pages (from-to) | 57-60 |
Number of pages | 4 |
Journal | British Journal of Haematology |
Volume | 178 |
Issue number | 1 |
DOIs | |
State | Published - Jul 1 2017 |
Keywords
- cytogenetics
- deletion 5q
- myelodysplastic syndrome
- prognostication
ASJC Scopus subject areas
- Hematology